



Market Announcement

8 June 2022

Avecho Biotechnology Limited (ASX: AVE) – Suspension of Options (ASX Code: AVEO) from Official Quotation

Description

The quoted options (ASX Code: AVEO) of Avecho Biotechnology Limited ('AVE') will be suspended from quotation immediately under Listing Rule 17.2, at the request of AVE, pending the release of a cleansing prospectus and court orders being obtained in relation to the options.

Please note that the suspension only applies to the quoted options (ASX Code: AVEO), and does not apply to any other quoted securities of AVE.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)

8 June 2022

Australian Securities Exchange
Level 4, North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

Via email: TradingHaltsMelbourne@asx.com.au; melissa.kostopoulos@asx.com.au

REQUEST FOR VOLUNTARY SUSPENSION

Melbourne, Australia, 8 June 2022 – In accordance with ASX Listing Rule 17.2, Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) requests that the Company’s class of quoted options (“AVEO”) be put in voluntary suspension effective immediately.

The Company recently became aware that, due to an administrative oversight, the AVEO securities were issued without disclosure and at the time remained subject to secondary trading restrictions under the *Corporations Act 2001* (Cth). The voluntary suspension is being sought to allow the Company to lodge a cleansing prospectus and to make an application to the court to seek declaratory relief and ancillary orders relating to prior trading in relation to the AVEO securities while they remained subject to secondary trading restrictions (“Court Orders”).

The Company advises that:

1. The voluntary suspension of the AVEO class will remain in place until the release of a cleansing prospectus on the quoted options and the Court Orders being obtained.
2. It expects that the Court Orders will take approximately 3 to 4 weeks to obtain.
3. It is not aware of any reason why the voluntary suspension should not be granted.

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

Yours sincerely



Ms Melanie Leydin
Company Secretary
Avecho Biotechnology Limited
+61 3 9002 5000

About Avecho

Avecho Biotechnology Limited (ASX: AVE) develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called TPM® (Tocopherol Phosphate Mixture). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho’s major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market, including the recently announced application of TPM® to cannabinoids. The Company is also developing TPM® to enhance feed efficiency and health of livestock.

See more here - avecho.com.au